The combination of Roche's Avastin and Tarceva helped people with a specific form of lung cancer live longer without their disease worsening

Phase II study in Japanese patients with a specific type of lung cancer meets primary endpoint of improved progression-free survival with the combination of Avastin and Tarceva compared to Tarceva alone. Roche today announced results from the phase II JO25567 study in which Avastin® (bevacizumab) was added to Tarceva® (erlotinib) as initial (first-line) treatment for people with advanced non-small cell lung cancer (NSCLC) characterised by activating mutations of the epidermal growth factor receptor (EGFR Mut+). Patients who received the combination in this study lived significantly longer without their disease getting worse (progression-free survival; PFS) compared to those given Tarceva alone. The results suggest that combining Avastin and Tarceva (anti-angiogenic and EGFR mutation-directed therapies) can provide significant clinical benefit beyond that provided by Tarceva alone for patients with EGFR Mut+ NSCLC.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news